FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379980188> ?p ?o ?g. }

• W4379980188 endingPage "94" @default.
• W4379980188 startingPage "93" @default.
• W4379980188 abstract "Introduction: Higher disease burden is associated with poor chimeric antigen receptor T-cell (CAR T) outcomes. Bridging therapy (BT) is widely used to debulk or palliate between apheresis and CAR T infusion. We studied whether the dynamics of radiomic cytoreduction during bridging are prognostic. Methods: Large B-cell lymphoma (LBCL) patients (pts) treated with anti-CD19 CAR T cells were stratified into 4 BT groups: (1) no BT (2) systemic therapy (ST) (including steroids) (3) radiotherapy (RT) and (4) combined ST/RT. To better assess the impact of BT, we created an MTV analysis cohort of pts who received BT and had repeat PET post-BT but pre-CAR T infusion. Max SUV and total metabolic tumor volume (MTV) using an automated method and SUV4 threshold were calculated for all pts off the pre-apheresis PET and for the analysis cohort on the post-BT PET. Pts in the analysis cohort were ordered into equal sized tertiles by absolute MTV amount first pre-apheresis and then again post-BT. To quantify impact of BT cytoreduction, we created 5 risk groups from the analysis cohort per degree of MTV change during BT: (a) High MTV (highest MTV tertile both pre and post BT) (b) Mid MTV (middle tertile pre and post BT) (c) Low MTV (lowest tertile pre and post BT) (d) Improved MTV (tertile decreased post BT) and (e) Progressing MTV (tertile increased post BT). Overall survival (OS) post-CAR T was estimated by Kaplan Meier. Results: 198 pts with LBCL (80%), high grade BCL (17%) or primary mediastinal BCL (3%) received CAR T (49% axicabtagene, 32% tisagenlecleucel, 19% lisocabtagene). Max SUV at apheresis was 18.5 (interquartile range, IQR 9.8 – 25.3) and MTV was 45.7 (IQR 5.7–167). 51 (26%) received no BT, 116 (59%) had ST, 20 (10%) had RT, 11 (6%) had ST/RT. Median OS was 13.9 mo overall, and 20.6 mo, 12.1 mo, 26.4 mo and 5.5 mo for the no BT, ST, RT and ST/RT groups, respectively. The MTV analysis cohort included 112/147 BT (76%) pts (n = 88 ST, n = 16 RT, n = 8 CMT). Median baseline max SUV was 20.0 (IQR 13.7—26.1), which was reduced 28% to 14.4 (IQR 5.5—22.1) post-BT. Median baseline MTV was 67.2cc (IQR 15.0—218.7) which was reduced 42% to 39.0cc (IQR 2.1—235.2) post-BT. Roughly half (53%) had any degree of quantitative cytoreduction post-BT (Figure A). The MTV burden both pre-apheresis and post-BT was significantly associated with post-CAR T OS (Figure B, C, p = 0.004, p < 0.0001, respectively). Median OS for the High MTV (n = 22), Mid MTV (n = 17) and Low MTV (n = 22), Improved MTV (n = 24) and Progressing MTV (n = 27) risk groups was 4.1, 15.5, 21.6, 13.6 and 10.1 mo, respectively (Figure D). The research was funded by: The Leukemia and Lymphoma Society Translational Research Program (TRP), the Memorial Sloan Kettering Cancer Center Comedy versus Cancer Grant Program, the Connecticut Cancer Foundation, the Steven A. Greenberg Award in Lymphoma, as well as the Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]. Keywords: cellular therapies, PET-CT, radiation therapy Conflicts of interests pertinent to the abstract G. L. Shah Consultant or advisory role: DSMB for ArcellX Research funding: Research funding to the institution from Janssen, Amgen, Beyond Spring, and BMS P. B. Dahi Consultant or advisory role: Curio Science LLC, Kite Pharmaceuticals, OncLive, Targeted Oncology S. Giralt Consultant or advisory role: Amgen, Actinuum, Celgene, Johnson & Johnson, Janssen, JAZZ Pharmaceuticals, Takeda, Novartis, Kite, Spectrum Pharma Research funding: Amgen, Actinuum, Celgene, Johnson & Johnson, Miltenyi, Takeda, Omeros M. Scordo Consultant or advisory role: McKinsey & Company, Angiocrine Bioscience, Inc., and Omeros Corporation, Kite – A Gilead Company Honoraria: i3Health and Medscape for CME-related activity Research funding: Angiocrine Bioscience, Inc., and Omeros Corporation G. Salles Consultant or advisory role: Abbvie, Atbtherapeutics, Bayer, Beigene, BMS/Celgene, Debiopharm, Epizyme, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Molecular Partners, Morphosys, Nordic Nanovector, Novartis, Regeneron, Takeda Stock ownership: Owkin M. L. Palomba Consultant or advisory role: Synthekine, Cellectar, Beigene, Kite, BMS M. Perales Consultant or advisory role: on DSMBs for Cidara Therapeutics, Medigene, and Sellas Life Sciences, and the scientific advisory board of NexImmune Stock ownership: NexImmune, Omeros and OrcaBio Honoraria: Adicet, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Syncopation, VectivBio AG, and Vor Biopharma Research funding: institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis" @default.
• W4379980188 created "2023-06-10" @default.
• W4379980188 creator A5007588773 @default.
• W4379980188 creator A5015672299 @default.
• W4379980188 creator A5016764336 @default.
• W4379980188 creator A5021595775 @default.
• W4379980188 creator A5023480510 @default.
• W4379980188 creator A5023759382 @default.
• W4379980188 creator A5033021913 @default.
• W4379980188 creator A5033851673 @default.
• W4379980188 creator A5045167741 @default.
• W4379980188 creator A5047384277 @default.
• W4379980188 creator A5048500214 @default.
• W4379980188 creator A5052204597 @default.
• W4379980188 creator A5052659722 @default.
• W4379980188 creator A5054664737 @default.
• W4379980188 creator A5063928576 @default.
• W4379980188 creator A5067154927 @default.
• W4379980188 creator A5070096873 @default.
• W4379980188 creator A5074706721 @default.
• W4379980188 creator A5075022242 @default.
• W4379980188 creator A5082608808 @default.
• W4379980188 creator A5089876625 @default.
• W4379980188 date "2023-06-01" @default.
• W4379980188 modified "2023-10-12" @default.
• W4379980188 title "DYNAMICS OF RADIOMIC FEATURES FOLLOWING BRIDGING THERAPY DETERMINE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY OUTCOME" @default.
• W4379980188 doi "https://doi.org/10.1002/hon.3163_57" @default.
• W4379980188 hasPublicationYear "2023" @default.
• W4379980188 type Work @default.
• W4379980188 citedByCount "0" @default.
• W4379980188 crossrefType "journal-article" @default.
• W4379980188 hasAuthorship W4379980188A5007588773 @default.
• W4379980188 hasAuthorship W4379980188A5015672299 @default.
• W4379980188 hasAuthorship W4379980188A5016764336 @default.
• W4379980188 hasAuthorship W4379980188A5021595775 @default.
• W4379980188 hasAuthorship W4379980188A5023480510 @default.
• W4379980188 hasAuthorship W4379980188A5023759382 @default.
• W4379980188 hasAuthorship W4379980188A5033021913 @default.
• W4379980188 hasAuthorship W4379980188A5033851673 @default.
• W4379980188 hasAuthorship W4379980188A5045167741 @default.
• W4379980188 hasAuthorship W4379980188A5047384277 @default.
• W4379980188 hasAuthorship W4379980188A5048500214 @default.
• W4379980188 hasAuthorship W4379980188A5052204597 @default.
• W4379980188 hasAuthorship W4379980188A5052659722 @default.
• W4379980188 hasAuthorship W4379980188A5054664737 @default.
• W4379980188 hasAuthorship W4379980188A5063928576 @default.
• W4379980188 hasAuthorship W4379980188A5067154927 @default.
• W4379980188 hasAuthorship W4379980188A5070096873 @default.
• W4379980188 hasAuthorship W4379980188A5074706721 @default.
• W4379980188 hasAuthorship W4379980188A5075022242 @default.
• W4379980188 hasAuthorship W4379980188A5082608808 @default.
• W4379980188 hasAuthorship W4379980188A5089876625 @default.
• W4379980188 hasBestOaLocation W43799801881 @default.
• W4379980188 hasConcept C121608353 @default.
• W4379980188 hasConcept C126322002 @default.
• W4379980188 hasConcept C141071460 @default.
• W4379980188 hasConcept C143998085 @default.
• W4379980188 hasConcept C147483822 @default.
• W4379980188 hasConcept C203014093 @default.
• W4379980188 hasConcept C2777701055 @default.
• W4379980188 hasConcept C2778957590 @default.
• W4379980188 hasConcept C3875195 @default.
• W4379980188 hasConcept C509974204 @default.
• W4379980188 hasConcept C71924100 @default.
• W4379980188 hasConcept C72563966 @default.
• W4379980188 hasConcept C90924648 @default.
• W4379980188 hasConceptScore W4379980188C121608353 @default.
• W4379980188 hasConceptScore W4379980188C126322002 @default.
• W4379980188 hasConceptScore W4379980188C141071460 @default.
• W4379980188 hasConceptScore W4379980188C143998085 @default.
• W4379980188 hasConceptScore W4379980188C147483822 @default.
• W4379980188 hasConceptScore W4379980188C203014093 @default.
• W4379980188 hasConceptScore W4379980188C2777701055 @default.
• W4379980188 hasConceptScore W4379980188C2778957590 @default.
• W4379980188 hasConceptScore W4379980188C3875195 @default.
• W4379980188 hasConceptScore W4379980188C509974204 @default.
• W4379980188 hasConceptScore W4379980188C71924100 @default.
• W4379980188 hasConceptScore W4379980188C72563966 @default.
• W4379980188 hasConceptScore W4379980188C90924648 @default.
• W4379980188 hasIssue "S2" @default.
• W4379980188 hasLocation W43799801881 @default.
• W4379980188 hasOpenAccess W4379980188 @default.
• W4379980188 hasPrimaryLocation W43799801881 @default.
• W4379980188 hasRelatedWork W1619537825 @default.
• W4379980188 hasRelatedWork W2580377636 @default.
• W4379980188 hasRelatedWork W2952578922 @default.
• W4379980188 hasRelatedWork W3004611567 @default.
• W4379980188 hasRelatedWork W3018061029 @default.
• W4379980188 hasRelatedWork W3177641494 @default.
• W4379980188 hasRelatedWork W3188370826 @default.
• W4379980188 hasRelatedWork W4249018146 @default.
• W4379980188 hasRelatedWork W4283270985 @default.
• W4379980188 hasRelatedWork W4385294737 @default.
• W4379980188 hasVolume "41" @default.
• W4379980188 isParatext "false" @default.
• W4379980188 isRetracted "false" @default.
• W4379980188 workType "article" @default.